Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, MD, PhD
Published: Thursday, Jun 30, 2016



Maria-Victoria Mateos, consultant physician, hematology department, Hospital Universitario de Salamanca, MD, PhD, discusses the TOURMALINE-MM1 trial in multiple myeloma.
 
The phase III trial investigated the impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
 
The IRd combination resulted in a significant improvement in progression free survival (PFS) compated to the control arm, says Mateos.
 
The benefit was sustained across different groups of patients regardless of prior lines of therapy.
 


Maria-Victoria Mateos, consultant physician, hematology department, Hospital Universitario de Salamanca, MD, PhD, discusses the TOURMALINE-MM1 trial in multiple myeloma.
 
The phase III trial investigated the impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) compared to placebo plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
 
The IRd combination resulted in a significant improvement in progression free survival (PFS) compated to the control arm, says Mateos.
 
The benefit was sustained across different groups of patients regardless of prior lines of therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x